摘要
No AccessJournal of UrologyAdult Urology1 Jan 2021Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence Rafael Castilho Borges, Rafael Rocha Tourinho-Barbosa, Sidney Glina, Petr Macek, Annick Mombet, Rafael Sanchez-Salas, and Xavier Cathelineau Rafael Castilho BorgesRafael Castilho Borges Department of Urology, Institut Mutualiste Montsouris, Paris, France Department of Urology, Faculdade de Medicina do ABC, São Paulo, Brazil More articles by this author , Rafael Rocha Tourinho-BarbosaRafael Rocha Tourinho-Barbosa Department of Urology, Institut Mutualiste Montsouris, Paris, France Department of Urology, Hospital Cardiopulmonar, Salvador, Brazil More articles by this author , Sidney GlinaSidney Glina Department of Urology, Faculdade de Medicina do ABC, São Paulo, Brazil More articles by this author , Petr MacekPetr Macek Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author , Annick MombetAnnick Mombet Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author , Rafael Sanchez-SalasRafael Sanchez-Salas *Correspondence: Department of Urology, Institut Mutualiste Montsouris, 42, Boulevard Jourdan, 75674Paris, France telephone: +33-1-56-61-62-63; E-mail Address: [email protected] Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author , and Xavier CathelineauXavier Cathelineau Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001327AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Focal instead of whole gland ablation for prostate cancer has been proposed to decrease treatment morbidity. We sought to determine differences in erectile function and urinary continence after focal and whole gland ablation for prostate cancer. Materials and Methods: From 2009 to 2018, 346 patients underwent high intensity focused ultrasound or cryotherapy for prostate cancer. Urinary continence was defined as use of no pads and sexual potency as enough erection for sexual penetration. Logistic regressions to treatment groups and covariates age, prostate specific antigen, International Society of Urological Pathology grading, prostate volume and energy modality were performed to access the effect of focal therapy in sexual potency and urinary continence after 3 and 12 months. IIEF-5 (International Index of Erectile Function) and I-PSS (International Prostate Symptom Score) questionnaires were evaluated. Propensity score matching was performed to adjust for potential baseline differences between groups. Results: After exclusion, 195 post-focal therapy and 105 post-whole gland therapy patients were included in analysis. No significant difference was seen in baseline I-PSS and IIEF-5 scores. In multivariate models focal therapy was the most important factor related to sexual potency at 3 (OR 7.7) and 12 months (OR 3.9). Median IIEF-5 score at 3 months was 12 and 5 (p <0.001), and at 12 months was 13 and 9 (p=0.04) in focal therapy and whole gland therapy groups, respectively. Focal therapy was the only factor related to continence (OR 0.7, p <0.001). Results remained significant after propensity score matching. Conclusions: Focal ablation instead of whole gland therapy is the most important factor related to better sexual and urinary continence recovery after high intensity focused ultrasound and cryotherapy for prostate cancer. References 1. : The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?J Urol 2004; 172: 1297. Link, Google Scholar 2. : Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203. Google Scholar 3. : Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272. Google Scholar 4. : The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 2014; 66: 732. Google Scholar 5. : Focal therapy for prostate cancer: an “A la Carte” approach. Eur Urol 2016; 69: 973. Google Scholar 6. : Focal cryotherapy: step by step technique description. Int Braz J Urol 2017; 43: 995. Google Scholar 7. : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205. Google Scholar 8. : Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. J Urol 2015; 193: 103. Link, Google Scholar 9. : Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 2014; 65: 907. Google Scholar 10. : Comparisons of oncological and functional outcomes between primary whole-gland cryoablation and high-intensity focused ultrasound for localized prostate cancer. Ann Surg Oncol 2016; 23: 328. Google Scholar 11. : Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622. Google Scholar 12. : Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013; 112: 322. Google Scholar 13. : Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer. J Urol 2014; 191: 1764. Link, Google Scholar 14. : Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013; 63: 618. Google Scholar 15. : Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 2015; 68: 927. Google Scholar 16. : Primary zonal high intensity focused ultrasound for prostate cancer: results of a prospective phase IIa feasibility study. Prostate Cancer 2014; 2014: 756189. Google Scholar 17. : The effects of focal therapy for prostate cancer on sexual function: a combined analysis of three prospective trials. Eur Urol 2016; 69: 844. Google Scholar 18. : Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol 2018; 199: 983. Link, Google Scholar 19. : Comparison of penile size and erectile function after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer: a prospective pilot study. J Sex Med 2010; 7: 3135. Google Scholar 20. : Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 2007; 70: 9. Google Scholar 21. : Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62: 55. Google Scholar 22. : Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012; 109: 1648. Google Scholar 23. : A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: the INDEX study. Contemp Clin Trials 2013; 36: 68. Google Scholar 24. : Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol 2016; 69: 214. Google Scholar 25. : Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 2017; 71: 267. Google Scholar 26. : Oncologic and functional outcomes of partial gland ablation with high intensity focused ultrasound for localized prostate cancer. J Urol 2019; 201: 113. Link, Google Scholar 27. : Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU Int 2009; 103: 788. Google Scholar No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited BySmith J (2020) This Month in Adult UrologyJournal of Urology, VOL. 205, NO. 1, (1-3), Online publication date: 1-Jan-2021. Volume 205Issue 1January 2021Page: 129-136Supplementary Materials Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmsurinary incontinenceerectile dysfunctionhigh-intensity focused ultrasound ablationcryotherapyMetricsAuthor Information Rafael Castilho Borges Department of Urology, Institut Mutualiste Montsouris, Paris, France Department of Urology, Faculdade de Medicina do ABC, São Paulo, Brazil More articles by this author Rafael Rocha Tourinho-Barbosa Department of Urology, Institut Mutualiste Montsouris, Paris, France Department of Urology, Hospital Cardiopulmonar, Salvador, Brazil More articles by this author Sidney Glina Department of Urology, Faculdade de Medicina do ABC, São Paulo, Brazil More articles by this author Petr Macek Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author Annick Mombet Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author Rafael Sanchez-Salas Department of Urology, Institut Mutualiste Montsouris, Paris, France *Correspondence: Department of Urology, Institut Mutualiste Montsouris, 42, Boulevard Jourdan, 75674Paris, France telephone: +33-1-56-61-62-63; E-mail Address: [email protected] More articles by this author Xavier Cathelineau Department of Urology, Institut Mutualiste Montsouris, Paris, France More articles by this author Expand All No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Advertisement Loading ...